Morning movers: ABCL gains 5.8% before trial data

Macro context is in today's Morning Read. This brief uses delayed Nasdaq pre-market quotes at 05:40-05:41 ET on 10 August 2026, independently checked against TradingView.

ABCL: +5.77% before a binary clinical readout

AbCellera’s SEC-filed release says it will publish top-line Phase 2 data for ABCL635 before today’s open and hold a webcast at 07:30 ET. The roughly 80-participant, randomized, double-blind, placebo-controlled study tests a non-hormonal antibody for moderate-to-severe vasomotor symptoms due to menopause. The schedule and design are verified; efficacy and safety results were not available at 05:40 ET.

• Why it moves: the stock is repricing probabilities before a clinical result, not verified efficacy data.
• Objective levels: the $7.1766-$7.59 delayed range and the $6.93 prior close.
• What to watch: the primary endpoint, safety profile, dose response and the company’s stated next development step.
• Main risk: an ambiguous or negative readout can reverse the full pre-market move.

MNDY: +3.30% before the quarterly report

monday.com’s investor-relations feed confirms that second-quarter 2026 results are due this morning, followed by a call at 08:30 ET. Nasdaq’s earnings calendar independently lists MNDY before the open. At 05:40 ET, the company feed still showed the announcement rather than the result package, so no revenue, earnings or guidance surprise is inferred here.

• Why it moves: the bid is event positioning, not a verified earnings beat.
• Objective levels: the $94.00-$97.92 delayed range and the $93.13 prior close.
• What to watch: growth, retention, AI-product adoption, margins and the full-year outlook on the 08:30 ET call.
• Main risk: the pre-event gain can disappear if guidance or customer metrics disappoint.

RKLB: +4.01% ahead of results after the close

Nasdaq’s calendar lists Rocket Lab’s June-quarter report for after the close today. The stock was already coming off a strong prior session, so the current move is treated as pre-earnings positioning rather than a fresh operating result. No unverified backlog, launch, Neutron or consensus number is used as the cause.

• Why it moves: investors are carrying momentum into a scheduled report; no new result was verified.
• Objective levels: the $84.75-$86.74 delayed range and the $82.83 prior close.
• What to watch: the filed result package and management commentary after the close; ignore unsourced preview numbers.
• Main risk: a high-expectation setup can reverse even when headline growth is positive.

Also on the radar

• MRNA +4.43% at $61.79 near 05:41 ET: Nasdaq and TradingView agreed on the direction and approximate level, but no current tier-1 catalyst was confirmed; treat it as sentiment-driven until a primary source appears.
• AAOI +6.13% at $143.95 near 05:41 ET: the move extended the reaction to its 6 August results, which reported record Q2 revenue and an 800G production ramp. It was already on Friday’s radar and has no new primary event here.
• ASTS +1.25% at $72.84 near 05:40 ET: Nasdaq lists results after today’s close. It shares the space-earnings theme with RKLB, so it stays in one radar line rather than becoming a duplicate feature story.

What to watch today

• 07:30 ET — ABCL: read the primary clinical release before interpreting the stock gap.
• 08:30 ET — MNDY: compare the actual quarter and outlook with the pre-event price range, not with social headlines.
• 09:30 ET — opening auction: regular-session liquidity can reset every delayed range immediately.
• After the close — RKLB and ASTS: use filed issuer results; do not carry pre-event option figures forward.
• Unverified analyst actions, social-engagement counts, historical pre-market baselines and executable pre-market option metrics were excluded.